| 1 |
AlTurki A, Marshall HJ, Proietti R. Targeting nonpulmonary vein triggers during atrial fibrillation ablation: is the game worth the candle? Curr Opin Cardiol 2018;33:50-7.
DOI
|
| 2 |
Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2017;14:e275-444.
DOI
|
| 3 |
Balk EM, Garlitski AC, Alsheikh-Ali AA, Terasawa T, Chung M, Ip S. Predictors of atrial fibrillation recurrence after radiofrequency catheter ablation: a systematic review. J Cardiovasc Electrophysiol 2010;21:1208-16.
DOI
|
| 4 |
Tang RB, Yan XL, Dong JZ, et al. Predictors of recurrence after a repeat ablation procedure for paroxysmal atrial fibrillation: role of left atrial enlargement. Europace 2014;16:1569-74.
DOI
|
| 5 |
AbouEzzeddine OF, McKie PM, Dunlay SM, et al. Suppression of tumorigenicity 2 in heart failure with preserved ejection fraction. J Am Heart Assoc 2017;6:e004382.
|
| 6 |
Aimo A, Vergaro G, Passino C, et al. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: a meta-analysis. JACC Heart Fail 2017;5:280-6.
DOI
|
| 7 |
Aimo A, Vergaro G, Ripoli A, et al. Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure. JACC Heart Fail 2017;5:287-96.
DOI
|
| 8 |
Eggers KM, Armstrong PW, Califf RM, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J 2010;159:788-94.
DOI
|
| 9 |
Okar S, Kaypakli O, Sahin DY, Koc M. Fibrosis marker soluble ST2 predicts atrial fibrillation recurrence after cryoballoon catheter ablation of nonvalvular paroxysmal atrial fibrillation. Korean Circ J 2018;48:920-9.
DOI
|
webmaster
